Nijmegen breakage syndrome (NBS) is a chromosomal instability disorder, clinically characterised by microcephaly, immunodeficiency, radiosensitivity and a very high predisposition to lymphoid malignancy. Recently, it was demonstrated that mutations in the NBS1 gene are responsible for NBS. Most of the NBS patients known so far are of Slav origin and carry a major founder mutation 657del5 in exon 6 of the NBS1 gene. In this study we estimated the prevalence of the 657del5 mutation in the Czech Republic, Poland and the Ukraine. We found an unexpectedly high carrier frequency of the 657del5 mutation (1/177) in the three Slav populations, a factor that may contribute to cancer frequency in those countries. In addition, we show that NBS patients are often diagnosed late and therefore receive inappropriate therapy. European Journal of Human Genetics (2000) 8, 900-902.
Introduction
Recently, mutations in the gene coding for nibrin were shown to be responsible for Nijmegen breakage syndrome (NBS), a relatively rare chromosomal instability disorder clinically characterised by microcephaly, immunodeficiency, growth retardation and high susceptibility to lymphoid malignancy. 1 Cells derived from NBS patients are hypersensitive to ionising radiation and exhibit a defect of cellcycle control. Nibrin is a member of the hMRE11/RAD50 protein complex which has been implicated in the repair of DNA double-strand breaks and recombination. 2 The majority of NBS patients are of Slav origin and carry the major founder mutation 657del5 in exon 6 of the NBS1 gene. We found this mutation on both chromosomes in 82 of 84 unrelated NBS patients analysed thus far, most of whom originate from Poland and the Czech Republic. Based on epidemiological data it has been suggested that NBS heterozygotes also have an elevated cancer risk, 3 similar to that in another related chromosomal instability syndrome, ataxia telangiectasia (AT). Increased risk of cancer for AT heterozygotes, in particular of breast cancer, 4 chronic lymphocytic leukaemia (B-CLL) 5, 6 and T-cell prolymphocytic leukaemia (T-PLL) 7 has been described. Clinical and especially cell biology similarities between NBS and AT, combined with the existence of a single major NBS founder mutation prompted us to estimate the general population frequency of the 657del5 mutation in three Slav populations -the Czech, Polish and Ukraniansand so to evaluate the potential impact of the suggested cancer risk for NBS heterozygotes.
Materials and methods
We analysed a total of 4416 randomly selected anonymous Guthrie cards drawn from newborn screening programmes -2274 from Poland, 1234 from the Czech Republic and 908 from the Ukraine (Lvov region). All samples were analysed for the 657del5 mutation by PCR-single strand conformation polymorphism (PCR-SSCP) analysis. A piece of approximately 2 mm in diameter was cut from each Guthrie card and used in a PCR reaction with fluorescently labelled (Fam) primers, flanking exon 6 of the NBS1 gene. The amplicons were electrophoresed on non-denaturing polyacrylamide gels as previously described. 1 All positive samples were confirmed by direct sequencing.
Results
We found 25 carriers of the 657del5 mutation in 4416 Guthrie cards (Table 1) , a mean prevalence of 1/177 for the three populations tested. The highest prevalence of heterozygotes was found in the Czech population (1/154), whilst heterozygote frequencies for the Polish and the Ukrainian populations (Lvov region) were somewhat lower -1/190 and 1/182, respectively. These frequencies are much higher than 1/866 recently reported for the same mutation in Germany. 8 Mean age at diagnosis was around 7 years in both the Czech and the Polish patients ( Table 2 ). The leading symptom was microcephaly which was seen in all but one patient. One third of the Czech and 15% of the Polish patients had already manifest malignancies at diagnosis.
Discussion
Unexpectedly, we found a high carrier frequency for the 657del5 mutation in the three Slav populations tested.
However, marked regional differences were observed in the Polish sample, with the highest prevalence of heterozygotes found in the area of Nowy Sacz (1/90). Epidemiological data indicate that in Poland a total of 46 NBS patients from 37 families have been diagnosed during the last 20 years from 12 million recorded live births. The differing regional distribution of NBS heterozygotes allows no precise estimation of the incidence of expected homozygotes in Poland. The situation is different in the former Czechoslovakia, where 16 NBS families are randomly distributed (11 from Czechia and 5 from Slovakia). Moreover, the analysed pool of Guthrie cards can be considered representative for Czechia since it comprises samples originating from almost all parts of the country. Thus the incidence of NBS patients can be estimated at 1/95 000 live-births based on this carrier frequency.
The number of patients diagnosed is clearly lower than expected. In the period between 1981 and 1995, during which clinical ascertainment of NBS probands can be considered constant, a total of seven index cases from six families were diagnosed in Czechia from 1.9 million recorded live births. Due to delayed diagnosis however, only three were actually born in this period. If those four probands for whom diagnosis was made after 1995 are included, the number of cases resorts to seven. Thus, according to the rough calculation, the frequency of diagnosed NBS patients was 1/271 000, and clearly lower than expected (1/95 000).
In principle, the observed discrepancy between the expected and observed number of NBS patients can be either due to selection against affected foetuses, reduced fertility of NBS gene carriers or underdiagnosis. The first two assumptions, however, are somewhat unlikely. The rate of spontaneous abortions in Polish and Czech NBS families with 6 in 107 or 1 in 55 pregnancies was even lower than in the general population with more than 10%. 9 In addition, the mean number of children in these families was about three (37 Polish and 16 Czech NBS families with 107 and 55 children, respectively), which is not indicative of reduced fertility. Thus, the most likely explanation for the observed discrepancy is underdiagnosis. It can be explained by the rarity of the disease and its relatively mild phenotype. This assumption is supported by the late recognition of many NBS patients. Table 2 shows that in former Czechoslovakia and Poland the mean age at diagnosis is 7.1 ± 4.5 and 7.2 ± 6.3, respectively. At that time, 14-37% of the NBS patients had already developed a tumour. The extreme radiosensitivity of NBS patients together with delayed diagnosis is a hidden danger, since patients with a malignancy are subjected to chemo-and radiotherapy which could lead to secondary tumours and even death. Therefore, it is absolutely essential to postulate criteria for the early and certain recognition of NBS in order to avoid the conventional treatment protocols in cases where a malignancy is already present. 10 This must hold not only for the Slav populations studied, but also for NBS patients 11 ) . Therefore, carriers of NBS1 mutation should avoid ionising radiation and also receive modified treatment protocols in cases of malignancy. In summary, this study provides the first data on frequencies of the 657del5 mutation in three Slav populations. We have also shown that the NBS patients are usually diagnosed late, which often gives rise to serious illness. The high incidence of the 657del5 mutation found here might be an important cancer risk factor for the Slav populations. The existence of a single mutation, however, offers an opportunity for easy and early detection of NBS patients and heterozygotes.
